AHA 2024: Zerlasiran shows promising Phase II results for elevated lipoprotein(a)
Zerlasiran was found to be well tolerated and no significant safety concerns were observed. Credit: Good dreams - Studio via ...
AHA 2024: Muvalaplin shows promising Phase II results for elevated serum lipoprotein(a)
"AHA 2024: Muvalaplin shows promising Phase II results for elevated serum lipoprotein (a)" was originally created and ...
FierceBiotech9h
Lilly's lipoprotein-blocking heart med posts midstage win, turning up heat on potential AZ showdown
A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...
STAT14h
Two drugs look promising for lipoprotein(a), a common genetic risk factor for heart disease
At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...
Zacks.com on MSN1h
LLY Oral Cholesterol Drug Lowers Lipoprotein Levels in Phase II Study
Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein (a) or Lp (a) levels in adults with high risk of cardiovascular events in a ...
Eli Lilly's Lipoprotein(a) Treatment Muvalaplin Meets Primary Endpoint in Trial
Eli Lilly said the treatment, a once-daily pill called muvalaplin, showed reductions in Lp (a) levels compared to placebo. Injectables are currently in Phase 3 development, but "these are the first ...
The American Journal of Managed Care3h
Psoriasis Risk Linked to Elevated Non-HDL to HDL Cholesterol Ratio, Study Finds
Data reveal a strong association between non–high-density lipoprotein (non-HDL) cholesterol to HDL cholesterol ratio and ...
Seeking Alpha on MSN1h
Viking phase 2b study of NASH candidate hits primary endpoint
In addition, reductions in triglycerides and atherogenic proteins such as apolipoprotein B (ApoB), lipoprotein (a) [Lp(a)], ...
Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose
Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a) [Lp(a)], a ...
STAT8h
A win for Apellis, a setback for Astellas
The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less ...
Healthy Returns: Eli Lilly's cholesterol pill impresses in mid-stage trial
The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...
Medical Xpress on MSN2h
Gastroesophageal reflux disease linked to cardiovascular risk factors: New insights from Mendelian randomization study
In terms of lipid profiles, the study indicated that GERD was associated with increased levels of low-density lipoprotein ...